Paul W. Erhardt, Ph.D.
 |
Paul W. Erhardt, Ph.D. Distinguished University Professor Emeritus Department of Medicinal & Biological Chemistry and Dept. of Cell and Cancer Biology paul.erhardt@utoledo.edu |
EDUCATION:
| B.A. | 1969 | Chemistry | University of Minnesota, Minneapolis |
| Ph.D. | 1974 | Medicinal Chemistry | University of Minnesota, Minneapolis |
| Post-Doc | 1975 | Bioanalytical Chemistry | University of Texas, Austin |
RESEARCH INTERESTS:
Anticancer agents, metabolic disorders (diabetes) and bone/cartilage homeostasis
PATENTS:
One of the compounds that I designed, synthesized and developed is marketed as Brevibloc®
(USAN: Esmolol Hydrochloride).
RECENT PUBLICATIONS: (co-author/inventor of more than 125 scientific papers/U.S. patents)
Malik, N., Zhang, Z. Erhardt, P. (2015) Total synthesis of (+)-glyceollin II and a dihydro derivative. J. Nat. Prod. 12:2940-2947.
Trabbic, C., Overmeyer, J.H., Alexander, E.M., Crissman E.J., Kvale H.M., Smith, M.A.,
Erhardt P.W. and Maltese, W.A. (2015) Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either
methuosis or microtubule disruption activity. J. Med. Chem. 58:2489-2512.
Trabbic, C., Dietsch, H., Alexander, E., Nagy,, P., Roinson, M., Overmeyer J., Maltese,
W. and Erhardt, P. (2014) Differential induction of cytoplasmic vacuolization and methuosis by novel 2-indolyl-substituted
pyridinylpropeones. ACS Med. Chem. Lett., 5:73-77.
Erhardt, P. (2014 & 2015). (I) Drug design and development: A research center more than twenty years in the making; & (ii) Drug design and development: Part II - reflections from an academic-based center. Chemistry International 36 & 37, pgs. (i) cover caption, 8-13,27-28; & (ii) 12-15.
Jetson, R., Malik, N., Luniwal, A., Chari, V., Ratnam, M., and Erhardt, P. (2013)
Practical synthesis of a chromene analog for use as a retinoic acid receptor alpha-antagonist
lead compound. Eur. J. Med. Chem., 63:104-108.
Nagy, P.I. and Erhardt, P. (2012) On the interaction of aliphatic amines and ammonium ions with carboxylic acids in
solution and in receptor pockets. J. Phys. Chem. B 116:5425-5436.
Luniwal, A., Wang, L., Pavlovsky, A., Erhardt, P. and Viola, R. (2012) Molecular docking and enzymatic evaluation to identify selective inhibitors of aspartate
semialdehde dehydrogenase. Bioorganic and Medicinal Chem., 20:2950-2956.
Sarver, J.G., Trendel, J.A., Bearss, N.R., Wang, L., Luniwal, A., Erhardt, W.W., and
Viola, R.E. (2012) Early stage efficacy and toxicology screening for antibiotics and enzyme inhibitors. J. Biomol. Screen. 17:673-682.
Robinson, M.W., Overmeyer, J.H., Young, A.M., Erhardt, P.W., and Maltese, W.A. (2012)
Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel
type of nonapoptotic cell death. J. Med. Chem. 55:1940-1956.
Luniwal, A., Khupse, R., Reese, M., Liu, J., El-Dakdouki, M., Malik, N., Fang, L.
and Erhardt, P. (2011) Multigram Synthesis of glyceollin I. Org. Process Res. Dev., 15:1149-1162.
Khupse, R., Sarver, J., Trendel, J., Bearss, N., Reese, M., Wiese, T., Boue, S., Burrow,
M., Cleveland, T., Bhatnagar, D. and Erhardt, P. (2011) Biomimetic synthesis and antiproliferative properties of racemic, natural (-) and
unnatural (+) glyceollin I. J. Med. Chem., 54:3506-3523.
El-Dakdouki,, M.H., Adamsi, N., Foster, L. Hacker, M.P., and Erhardt, P.W. (2011)
Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising
anticancer activity. J. Med. Chem. 54:8224-8227.
Shan, Y.Y., Zhang, C.M., Tang, L.Q., Liu, Z.P. Bearss, N.R., Sarver, J.G., Luniwal,
A. and Erhardt, P.W. (2011) Syntheses of 2,3-diarylated 2H-benzo[e][1,2]thiazine 1,1-dioxides and their 3,4-dihydro
derivatives, and assessment of their inhibitory activity against MCF-7 breast cancer
cells. Med. Chem. 7:561-571.